article thumbnail

Cybersecurity dominates pharma industry discussions during Q2 2023: GlobalData

Express Pharma

This pivotal juncture has thrust cybersecurity into the spotlight in the discussions of companies during Q2 2023, revealing its paramount significance in safeguarding sensitive information, with regulation mentions getting on par with data protection, reveals the Company Filing Analytics Database of GlobalData.

article thumbnail

2023 Medicare Updates – What You Need to Know

Community Pharmacy

For those who have Medicare on their mind, we will do a quick overview of how the program works before diving into the 2023 updates and notable changes you should be aware of as we head into the new year. If this applies to you, then you can begin your application process here to get the process started. for brand-name.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

2024 Medicare Updates – How We Can Help

Community Pharmacy

Created as an insurance coverage plan for those over 65, Medicare offers four levels of benefits that cover everything from hospital insurance to prescription medicine costs. 2024 Medicare Part D Costs Updates While the cost of Part D insurance premiums is expected to decrease from an average of $56.49 in 2023 to $55.50

article thumbnail

Drug price negotiations: pCPA consulting on a Temporary Access Process (pTAP)

Pharma in Brief

CADTH Time-Limited Reimbursement Recommendations Starting in the fall of 2023, CADTH, which conducts health technology assessments ( HTAs ) to inform public insurers, will introduce time-limited reimbursement recommendations for certain drug products. The deadline to provide input is August 18, 2023. Evidence-generation plans.

article thumbnail

Pharmacists Can Now Dispense Mifepristone Under Updated REMS Program

Birth Control Pharmacist

What Does the January 2023 Update Mean for Mifepristone Dispensing? As of January 2023, the US Food and Drug Administration (FDA) announced an update to the Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. Mifepristone is a medication that is used to end an early pregnancy. About the Author Amanda Idusuyi , Pharm.D

article thumbnail

Considerations for Hernia Patients when Selecting a Surgeon

Putting Patients First Blog

The Abdominal Core Health Quality Collaborative (ACHQC) believes it is our obligation to listen and offer suggestions to help patients navigate the decision-making process. Choose a surgeon who communicates clearly, listens attentively, and ensures you understand the procedure, potential risks, and recovery process.

article thumbnail

Lilly defers Alzheimer’s drug filing after CMS’ ‘disappointing’ decision

pharmaphorum

Lilly is a little vague on when it will now file donanemab with the FDA – suggesting on its fourth quarter 2021 results call that it may do so later this year – but reiterated that it has little hope of the drug being used ahead of the readout of TRAILBLAZER-ALZ 2 in mid-2023.